Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $185.00 price target.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Johnson & Johnson’s strong performance and strategic resilience. The company has started 2025 on a positive note, surpassing expectations in both revenue and earnings per share for the first quarter. This achievement is particularly noteworthy given the challenges posed by the Stelara biosimilar competition in the Pharma unit. Despite these headwinds, Johnson & Johnson has maintained its guidance for 2025, showcasing its ability to navigate market pressures effectively.
Another significant factor influencing the Buy rating is the robust performance of Johnson & Johnson’s Innovative Medicine segment, which exceeded market expectations and contributed to the company’s overall revenue growth. Although the MedTech division faced some temporary setbacks due to specific inventory and timing issues, the company is managing to absorb substantial tariff costs without altering its earnings guidance. This ability to mitigate external financial pressures, along with the anticipated foreign exchange benefits, reinforces the confidence in Johnson & Johnson’s financial outlook and underpins the Buy recommendation.
In another report released yesterday, Raymond James also maintained a Buy rating on the stock with a $162.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.